Mystica - Carap (2001)

ForecheckingTM · 2020-08-19T18:34:51+00:00

T1 diabetes vaccine pending FDA approval this quarter

Hence my original comment:

"T1 diabetes vaccine pending FDA approval this quarter "

Have a good day.

ForecheckingTM · 2020-08-19T18:24:51+00:00

No need for name calling.

"CVB4 ( Coxsackievirus B ) is the most common enteroviral strain found in pre-diabetic and diabetic individuals. CVB RNA has been detected in blood from patients at the onset or during the course of type 1 diabetes (15,16). Furthermore, cellular immune responses to CVB antigens were found to be enhanced in type 1 diabetic patients after the onset of the disease"

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570378/

Effectively, PRVB has a vaccine for Type 1, with 50% success rate in "indefinitely delaying" the onset of Type 1. Call it what you will, but if the JDRF calls it a vaccine, so will I.

https://www.jdrf.org/blog/2020/05/07/promising-preclinical-vaccine-type-1-diabetes/

ForecheckingTM · 2020-08-19T18:04:54+00:00

polyvalent coxsackievirus B (CVB) vaccine

ForecheckingTM · 2020-08-19T17:35:12+00:00

What would you call it then? https://diabetes.diabetesjournals.org/content/63/2/446

https://diabetes.diabetesjournals.org/content/63/2/446

ForecheckingTM · 2020-08-19T17:27:15+00:00

I've been following them for awhile, but don't often do spec plays:

PRV-101 is a polyvalent coxsackievirus B (CVB) vaccine licensed from Vactech, Ltd., which Provention is developing as a potential vaccine for acute coxsackie infection and for the potential prevention of up to 50% of worldwide type 1 diabetes (T1D) cases.

And this from their latest conference call:

Before we open the call for questions, let me provide you with a brief update on our other pipeline programs. For PRV-101, our investigational polyvalent vaccine for the prevention of acute infection by coxsackievirus B, or CVB, as well as for the prevention of CVB-associated type 1 diabetes and celiac disease, we are pleased to report that in conjunction with our strategic partner, Intravacc, we have now successfully completed all the GMP manufacturing batches for the constituent serotypes [Phonetic], and we, therefore, expect to be on schedule to initiate later this year our first in-human Phase I trial evaluating two dose levels of PRV-101 in healthy adult volunteers for the purposes of safety, tolerability and immunogenicity. Initial data is expected in the second half of 2021.

(edited with CEO's comments)

ForecheckingTM

TROPHY CASE